Cancer chemoprevention: scientific promise, clinical uncertainty
- 1 October 2005
- journal article
- research article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 2 (10) , 518-525
- https://doi.org/10.1038/ncponc0319
Abstract
Nature Clinical Practice Oncology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.Keywords
This publication has 58 references indexed in Scilit:
- Validating Stat3 in cancer therapyNature Medicine, 2005
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1Biochemical and Biophysical Research Communications, 2004
- The history of cancer epigeneticsNature Reviews Cancer, 2004
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- Inflammation and cancerNature, 2002
- Inflammation in atherosclerosisNature, 2002
- Points of control in inflammationNature, 2002